February 3, 2026 — Leads & Copy — CareDx, Inc. (Nasdaq: CDNA) announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® in Salt Lake City, Utah, held February 4-7, 2026.
The ACROBAT study is a prospective, multi-center, blinded clinical trial evaluating AlloHeme, CareDx’s AI-powered next-generation sequencing (NGS)-based peripheral blood test for monitoring relapse after allogeneic hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. AlloHeme identifies cancer relapse ahead of traditional detection methods, potentially enabling timely clinical interventions.
The ACROBAT study includes patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) monitored with AlloHeme for cancer relapse at 11 hematopoietic stem cell transplant centers across the U.S.
The oral presentation will feature the complete 24-month follow-up results, building upon 18-month interim results published in the conference abstract, available online.
CareDx will host an investor webcast and conference call on February 12, 2025, to discuss the study findings and commercial launch timeline.
Dr. Ran Reshef, Professor of Medicine at Columbia University and Director of Translational Research, Blood and Marrow Transplantation Program at Herbert Irving Comprehensive Cancer Center, will present the Acrobat Interim Results at Presentation ID 61. The presentation is titled: Peripheral Blood-Based AlloHeme Test Enables Robust Relapse Surveillance in Post-HCT AML and MDS Patients. The presentation will occur on Friday, February 6, 3:15 p.m. MT in Ballroom I, Salt Palace Convention Center.
The investor webcast, titled: AlloHeme Clinical Validation Data Review and Launch Timeline, will occur on Wednesday, February 12, 7 a.m. PT / 10 a.m. ET. Presentations will be given by members of CareDx’s leadership team and ACROBAT study site Principal Investigator, Dr. Ran Reshef.
A live and archived webcast can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, registration is available online.
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients.
Source: CareDx
